Relapsing Chronic Myelogenous Leukemia: Clinical Trials

35 trials for Relapsing Chronic Myelogenous Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 completed, 6 terminated. 35 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 135Completed 29, Terminated 6
Phase 26Completed 5, Terminated 1

Follow Relapsing Chronic Myelogenous Leukemia: new trials by email Literature Review of Relapsing Chronic Myelogenous Leukemia trials Research Report on Relapsing Chronic Myelogenous Leukemia

Trials (filtered) newest first · largest first

All 35 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Phase 1CompletedCity of Hope Medical Center362012-10-292024-04-02
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
therapeutic allogeneic lymphocytes - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Phase 1CompletedRobert Lowsky162012-01-012023-11-22
Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate
dasatinib, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Phase 1TerminatedNational Cancer Institute (NCI)42011-09-012014-04-02
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
fludarabine phosphate, methoxyamine, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Phase 1CompletedCase Comprehensive Cancer Center202011-05-012015-08-13
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage
Phase 1CompletedNational Cancer Institute (NCI)452011-01-012014-04-29
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Phase 1CompletedNational Cancer Institute (NCI)422009-08-012014-03-17
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia
Phase 1TerminatedNational Cancer Institute (NCI)222009-06-012014-05-01
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
nilotinib, imatinib mesylate, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Phase 1 / Phase 2CompletedFred Hutchinson Cancer Center402008-08-142017-08-10
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
GTI-2040, pharmacological study, laboratory biomarker analysis - Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Phase 1CompletedNational Cancer Institute (NCI)242007-03-012015-12-04
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases
decitabine, vorinostat, laboratory biomarker analysis - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Phase 1CompletedNational Cancer Institute (NCI)502006-06-012013-01-07
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
vorinostat, cytarabine, etoposide - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia
Phase 1CompletedNational Cancer Institute (NCI)252006-05-012013-05-03
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
vorinostat, idarubicin, laboratory biomarker analysis - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Phase 1CompletedNational Cancer Institute (NCI)402006-03-012013-09-30
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
dasatinib, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Phase 1CompletedNational Cancer Institute (NCI)482006-03-012013-02-05
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
alvocidib, vorinostat - Blastic Phase Chronic Myelogenous Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
Phase 1CompletedNational Cancer Institute (NCI)242006-01-012013-04-02
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
SJG-136 - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Phase 1TerminatedNational Cancer Institute (NCI)252005-12-012013-09-30
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
7-hydroxystaurosporine, perifosine, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
Phase 1CompletedNational Cancer Institute (NCI)302005-12-012013-09-30
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
vorinostat, isotretinoin - Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor
Phase 1CompletedNational Cancer Institute (NCI)602005-08-012014-06-17
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
imatinib mesylate, temsirolimus, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Phase 1TerminatedNational Cancer Institute (NCI)212005-04-012013-01-14
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
ispinesib, laboratory biomarker analysis, pharmacological study - Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
Phase 1CompletedNational Cancer Institute (NCI)402004-12-012013-01-11
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
tanespimycin, cytarabine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia
Phase 1CompletedNational Cancer Institute (NCI)422004-11-012013-09-30

Showing 20 of 35. Sign in to see all of them.

Narrower conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma (29)  ·  Leukemia, Myeloid, Acute (25)  ·  Blast Crisis (24)  ·  Congenital Abnormalities (19)  ·  Leukemia, Myeloid, Accelerated Phase (16)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (12)  ·  Leukemia, Myelomonocytic, Chronic (12)  ·  Burkitt Lymphoma (10)  ·  Leukemia, Myeloid, Chronic-Phase (10)  ·  Lymphoma, Large B-Cell, Diffuse (10)  ·  Anemia, Refractory, with Excess of Blasts (8)  ·  Lymphoma, Follicular (8)  ·  Lymphoma, Mantle-Cell (8)  ·  Mycosis Fungoides (8)  ·  Sezary Syndrome (8)

Broader conditions

Disease Attributes (35)  ·  Hematologic Diseases (35)  ·  Hemic and Lymphatic Diseases (35)  ·  Leukemia (35)  ·  Neoplasms by Histologic Type (35)  ·  Pathologic Processes (35)  ·  Pathological Conditions, Signs and Symptoms (35)  ·  Chronic Disease (34)  ·  Leukemia, Myeloid (34)  ·  Neoplasms (34)  ·  Bone Marrow Diseases (33)  ·  Immune System Diseases (29)  ·  Immunoproliferative Disorders (29)  ·  Leukemia, Lymphoid (29)  ·  Lymphatic Diseases (29)

Interventions

Vorinostat (5)  ·  Cytarabine (4)  ·  Imatinib Mesylate (4)  ·  Cyclosporine (2)  ·  Dasatinib (2)  ·  Flow Cytometry (2)  ·  Granulocyte-Macrophage Colony-Stimulating Factor (2)  ·  Interleukin-2 (2)  ·  Peripheral Blood Stem Cell Transplantation (2)  ·  aldesleukin (2)  ·  alvocidib (2)  ·  fludarabine phosphate (2)  ·  sargramostim (2)  ·  1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione) (1)  ·  3-aminopyridine-2-carboxaldehyde thiosemicarbazone (1)

Sponsors

National Cancer Institute (NCI) (28)  ·  Fred Hutchinson Cancer Center (4)  ·  Case Comprehensive Cancer Center (1)  ·  City of Hope Medical Center (1)  ·  Robert Lowsky (1)

Countries

United States (35)  ·  Canada (2)  ·  Germany (1)  ·  Italy (1)

Top investigators

Maryam Fouladi (3)  ·  Francis Giles (2)  ·  Jorge Cortes (2)  ·  Richard Aplenc (2)  ·  B. Smith (1)  ·  Brenda Cooper (1)  ·  Brenda Sandmaier (1)  ·  Christopher Porter (1)  ·  Douglas Ross (1)  ·  Ewa Carrier (1)  ·  Farhad Ravandi-Kashani (1)  ·  Guillermo Garcia-Manero (1)  ·  Gunnar Ragnarsson (1)  ·  Ivana Gojo (1)  ·  Jean-Pierre Issa (1)

Results publications

PMID 18974373, PMID 20460644, PMID 21791475, PMID 22259028, PMID 23393050, PMID 23443507, PMID 23660685, PMID 24474568, PMID 26853648, PMID 29572391, PMID 30562587, PMID 32499241

NIH funding

U01CA062461 (6), P01CA018029 (4), U01CA062505 (3), U01CA097452 (3), P30CA015704 (2), U01CA062502 (2), P01CA015396 (1), P30CA046934 (1), R01CA093891 (1), R21CA112936 (1), R21CA115260 (1), U01CA062487 (1), U01CA062490 (1), U01CA062491 (1), U01CA069852 (1)